Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients


Immunocore Holdings Plc IMCR announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid tumors.

  • IMC-C103C was developed using the Company's ImmTAC technology platform and is being developed in partnership with Genentech, a member of Roche Holdings AG RHHBY.
  • IMC-C103C demonstrated a manageable safety profile. The most common treatment-related adverse events were cytokine release syndrome and were dose-dependent and rapidly resolved. 
  • The most common severe adverse event was neutropenia, typically at doses over 90 micrograms. 
  • None of the treatment-related AEs led to discontinuation or death.
  • Data showed biomarkers of T cell activation consistent and robust at doses over 90 micrograms.
  • One ovarian cancer patient, with a very low MAGE protein expression, treated at a dose of less 90 micrograms, had a durable confirmed partial response (PR) with 8.3 months duration. 
  • An additional ovarian cancer patient at a dose of over 90 micrograms, with very low MAGE-A4 protein expression, has a confirmed partial response ongoing at 4.4+ months. 
  • One of the three non-ovarian cancer patients (head and neck squamous cell carcinoma) at a dose of over 90 micrograms has a confirmed PR that is ongoing.
  • Immunocore initiated an expansion arm in high-grade serous ovarian carcinoma at 140 micrograms. 
  • The Company plans to present additional data from this program in 2022. 
  • Price Action: IMCR shares are down 5.96% at $27 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 1 TrialSolid Tumor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!